Literature DB >> 28830118

Two Fatal Intoxications Involving 3-Methoxyphencyclidine.

Christie Mitchell-Mata1, Brittany Thomas2, Brianna Peterson2, Fiona Couper2.   

Abstract

3- and 4-methoxyphencyclidine (3-MeO-PCP, 4-MeO-PCP), structural analogs of phencyclidine (PCP), were among the first legal PCP alternatives to show up on the novel psychoactive substances (NPS) market in Europe in the 2000s. Their structural similarities to PCP and ketamine likely contribute to their demonstrated dissociative anesthetic effects. Limited information exists in the literature about toxic and lethal concentrations of these drugs in biological samples. This case report presents the first two death cases in Washington State in which 3-MeO-PCP was identified. Alkaline drug screen analysis by gas chromatography-mass spectrometry (GC-MS) revealed a peak with a retention time similar to PCP and base peak of m/z 230. Certified reference materials for 3-and 4-MeO-PCP were obtained and the isomers were able to be distinguished based on different retention times and mass spectra. A quantitative GC-MS method was developed and validated for casework, utilizing a dynamic range of 10-1,000 ng/mL and a limit of detection of 1 ng/mL. Postmortem (peripheral/central) blood samples were analyzed using this method and the resulting concentrations were 0.63 and 3.2 mg/L of 3-MeO-PCP. Methamphetamine (0.11 mg/L) was additionally detected in the blood of one of the decedents; while the second decedent was additionally positive for ethanol (0.047 g/100 mL), bupropion (1.8 mg/L), delorazepam, paroxetine and mitragynine. The results presented in this case report are higher than previously reported concentrations in fatal cases, but the presence of polysubstance abuse is consistent with previously reported NPS intoxications. Both of these individuals were in drug rehabilitation facilities prior to their deaths; however, users continue to be drawn to 3-MeO-PCP due to its dissociative effects and its accessibility on the internet.
© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28830118     DOI: 10.1093/jat/bkx048

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  6 in total

Review 1.  Interpol review of toxicology 2016-2019.

Authors:  Wing-Sum Chan; George Fai Wong; Chi-Wai Hung; Yau-Nga Wong; Kit-Mai Fung; Wai-Kit Lee; Kwok-Leung Dao; Chung-Wing Leung; Kam-Moon Lo; Wing-Man Lee; Bobbie Kwok-Keung Cheung
Journal:  Forensic Sci Int       Date:  2020-05-23       Impact factor: 2.395

2.  Intoxication by 3-MeO-PCP and O-desmethyltramadol: an unusual NPS mix.

Authors:  André Lobo Castro; Maria José C S Pinto da Costa; Sónia Tarelho; Lara Sousa; Fernando Russo; João Miguel Franco
Journal:  Int J Legal Med       Date:  2022-04-01       Impact factor: 2.791

Review 3.  Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017-2020: A Review.

Authors:  Amanda L A Mohr; Barry K Logan; Melissa F Fogarty; Alex J Krotulski; Donna M Papsun; Sherri L Kacinko; Marilyn A Huestis; Jeri D Ropero-Miller
Journal:  J Anal Toxicol       Date:  2022-07-14       Impact factor: 3.220

Review 4.  Intoxication with 3-MeO-PCP alone: A case report and literature review.

Authors:  Antoine Berar; Jean-Sébastien Allain; Sophie Allard; Charles Lefevre; Alain Baert; Isabelle Morel; Renaud Bouvet; Thomas Gicquel
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

5.  Case Report: Treatment of Kratom Use Disorder With a Classical Tricyclic Antidepressant.

Authors:  Alessandro E Vento; Simone de Persis; Sergio De Filippis; Fabrizio Schifano; Flavia Napoletano; John M Corkery; Georgios D Kotzalidis
Journal:  Front Psychiatry       Date:  2021-03-31       Impact factor: 4.157

Review 6.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.